vs
Side-by-side financial comparison of TEXAS CAPITAL BANCSHARES INC (TCBI) and Bio-Techne (TECH). Click either name above to swap in a different company.
TEXAS CAPITAL BANCSHARES INC is the larger business by last-quarter revenue ($324.0M vs $295.9M, roughly 1.1× Bio-Techne). TEXAS CAPITAL BANCSHARES INC runs the higher net margin — 22.8% vs 12.8%, a 9.9% gap on every dollar of revenue. On growth, TEXAS CAPITAL BANCSHARES INC posted the faster year-over-year revenue change (15.5% vs -6.4%). Over the past eight quarters, TEXAS CAPITAL BANCSHARES INC's revenue compounded faster (10.2% CAGR vs 4.2%).
Texas Capital Bank is a bank headquartered in Dallas, Texas. The bank has branches located in every major city in Texas. Its parent bank holding company is Texas Capital Bancshares. It also operates an online-only banking division, Bask Bank.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
TCBI vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $324.0M | $295.9M |
| Net Profit | $73.8M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | — | 18.4% |
| Net Margin | 22.8% | 12.8% |
| Revenue YoY | 15.5% | -6.4% |
| Net Profit YoY | 56.8% | 68.3% |
| EPS (diluted) | $1.56 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $324.0M | — | ||
| Q4 25 | $327.5M | $295.9M | ||
| Q3 25 | $340.4M | — | ||
| Q2 25 | $307.5M | $317.0M | ||
| Q1 25 | $280.5M | $316.2M | ||
| Q4 24 | $229.6M | $297.0M | ||
| Q3 24 | $125.3M | $289.5M | ||
| Q2 24 | $267.0M | $306.1M |
| Q1 26 | $73.8M | — | ||
| Q4 25 | $100.7M | $38.0M | ||
| Q3 25 | $105.2M | — | ||
| Q2 25 | $77.3M | $-17.7M | ||
| Q1 25 | $47.0M | $22.6M | ||
| Q4 24 | $71.0M | $34.9M | ||
| Q3 24 | $-61.3M | $33.6M | ||
| Q2 24 | $41.7M | $40.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
| Q1 26 | — | — | ||
| Q4 25 | 40.4% | 18.4% | ||
| Q3 25 | 40.5% | — | ||
| Q2 25 | 33.2% | -7.5% | ||
| Q1 25 | 21.6% | 12.2% | ||
| Q4 24 | 40.7% | 16.0% | ||
| Q3 24 | -63.8% | 13.8% | ||
| Q2 24 | 21.9% | 15.0% |
| Q1 26 | 22.8% | — | ||
| Q4 25 | 30.7% | 12.8% | ||
| Q3 25 | 30.9% | — | ||
| Q2 25 | 25.2% | -5.6% | ||
| Q1 25 | 16.8% | 7.1% | ||
| Q4 24 | 30.9% | 11.7% | ||
| Q3 24 | -48.9% | 11.6% | ||
| Q2 24 | 15.6% | 13.3% |
| Q1 26 | $1.56 | — | ||
| Q4 25 | $2.11 | $0.24 | ||
| Q3 25 | $2.18 | — | ||
| Q2 25 | $1.58 | $-0.11 | ||
| Q1 25 | $0.92 | $0.14 | ||
| Q4 24 | $1.43 | $0.22 | ||
| Q3 24 | $-1.41 | $0.21 | ||
| Q2 24 | $0.80 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $172.9M |
| Total DebtLower is stronger | $878.3M | $260.0M |
| Stockholders' EquityBook value | $3.6B | $2.0B |
| Total Assets | $33.5B | $2.5B |
| Debt / EquityLower = less leverage | 0.24× | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $172.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $162.2M | ||
| Q1 25 | — | $140.7M | ||
| Q4 24 | — | $177.5M | ||
| Q3 24 | — | $187.5M | ||
| Q2 24 | — | $152.9M |
| Q1 26 | $878.3M | — | ||
| Q4 25 | $620.6M | $260.0M | ||
| Q3 25 | $620.4M | — | ||
| Q2 25 | $620.3M | $346.0M | ||
| Q1 25 | $660.5M | $330.0M | ||
| Q4 24 | $660.3M | $300.0M | ||
| Q3 24 | $660.2M | $300.0M | ||
| Q2 24 | $660.0M | $319.0M |
| Q1 26 | $3.6B | — | ||
| Q4 25 | $3.6B | $2.0B | ||
| Q3 25 | $3.6B | — | ||
| Q2 25 | $3.5B | $1.9B | ||
| Q1 25 | $3.4B | $2.0B | ||
| Q4 24 | $3.4B | $2.1B | ||
| Q3 24 | $3.4B | $2.1B | ||
| Q2 24 | $3.2B | $2.1B |
| Q1 26 | $33.5B | — | ||
| Q4 25 | $31.5B | $2.5B | ||
| Q3 25 | $32.5B | — | ||
| Q2 25 | $31.9B | $2.6B | ||
| Q1 25 | $31.4B | $2.6B | ||
| Q4 24 | $30.7B | $2.7B | ||
| Q3 24 | $31.6B | $2.7B | ||
| Q2 24 | $29.9B | $2.7B |
| Q1 26 | 0.24× | — | ||
| Q4 25 | 0.17× | 0.13× | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | 0.18× | 0.18× | ||
| Q1 25 | 0.19× | 0.16× | ||
| Q4 24 | 0.20× | 0.14× | ||
| Q3 24 | 0.20× | 0.14× | ||
| Q2 24 | 0.21× | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TCBI
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
